OBJECTIVES: To investigate whether anti-Saccharomyces cerevisiae antibodies (ASCA), a marker for Crohn's disease (CD), are present in spondyloarthropathies (SpA) and in the subgroups ankylosing spondylitis (AS), undifferentiated SpA (uSpA), and psoriatic arthritis (PsA), in comparison with healthy and inflammatory controls (patients with rheumatoid arthritis (RA)). METHODS: ASCA IgA and IgG levels were measured with an enzyme linked immunosorbent assay (ELISA) kit (Medipan, Germany) in 26 patients with CD, 108 patients with SpA (43 patients with AS, 20 patients with uSpA, 45 patients with PsA), 56 patients with RA and 45 healthy controls. Gut biopsy samples were available in 18 AS and 10 patients with uSpA, these samples were screened for the presence of inflammation. RESULTS: Both ASCA IgG and IgA levels were raised in CD compared with healthy controls and patients with RA. ASCA IgA, but not IgG levels, were higher in SpA than in both healthy and RA controls. ASCA IgA levels were raised in AS and uSpA, but not in PsA. No significant differences in ASCA IgA levels were noted between patients with SpA with and without histological gut inflammation. CONCLUSION: ASCA IgA levels are significantly higher in SpA, and more specifically in AS, than in healthy controls and patients with RA. This is the first serum marker associated with SpA. No correlation between the presence of subclinical bowel inflammation and ASCA IgA levels was noted. However, it remains to be evaluated whether patients with SpA with ASCA have an increased risk of developing CD.
OBJECTIVES: To investigate whether anti-Saccharomyces cerevisiae antibodies (ASCA), a marker for Crohn's disease (CD), are present in spondyloarthropathies (SpA) and in the subgroups ankylosing spondylitis (AS), undifferentiated SpA (uSpA), and psoriatic arthritis (PsA), in comparison with healthy and inflammatory controls (patients with rheumatoid arthritis (RA)). METHODS: ASCA IgA and IgG levels were measured with an enzyme linked immunosorbent assay (ELISA) kit (Medipan, Germany) in 26 patients with CD, 108 patients with SpA (43 patients with AS, 20 patients with uSpA, 45 patients with PsA), 56 patients with RA and 45 healthy controls. Gut biopsy samples were available in 18 AS and 10 patients with uSpA, these samples were screened for the presence of inflammation. RESULTS: Both ASCA IgG and IgA levels were raised in CD compared with healthy controls and patients with RA. ASCA IgA, but not IgG levels, were higher in SpA than in both healthy and RA controls. ASCA IgA levels were raised in AS and uSpA, but not in PsA. No significant differences in ASCA IgA levels were noted between patients with SpA with and without histological gut inflammation. CONCLUSION: ASCA IgA levels are significantly higher in SpA, and more specifically in AS, than in healthy controls and patients with RA. This is the first serum marker associated with SpA. No correlation between the presence of subclinical bowel inflammation and ASCA IgA levels was noted. However, it remains to be evaluated whether patients with SpA with ASCA have an increased risk of developing CD.
Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: P Demetter; D Baeten; F De Keyser; M De Vos; N Van Damme; G Verbruggen; S Vermeulen; M Mareel; D Elewaut; H Mielants; E M Veys; C A Cuvelier Journal: Ann Rheum Dis Date: 2000-03 Impact factor: 19.103
Authors: F De Keyser; D Elewaut; M De Vos; K De Vlam; C Cuvelier; H Mielants; E M Veys Journal: Rheum Dis Clin North Am Date: 1998-11 Impact factor: 2.670
Authors: D Elewaut; F De Keyser; C Cuvelier; A I Lazarovits; H Mielants; G Verbruggen; S Sas; M Devos; E M Veys Journal: Scand J Gastroenterol Date: 1998-07 Impact factor: 2.423
Authors: B Sendid; J F Quinton; G Charrier; O Goulet; A Cortot; B Grandbastien; D Poulain; J F Colombel Journal: Am J Gastroenterol Date: 1998-08 Impact factor: 10.864
Authors: H Mielants; E M Veys; C Cuvelier; M De Vos; S Goemaere; L De Clercq; L Schatteman; L Gyselbrecht; D Elewaut Journal: J Rheumatol Date: 1995-12 Impact factor: 4.666
Authors: Alena V Kundzer; Margarita V Volkova; Dimitrios P Bogdanos; Stefan Rödiger; Peter Schierack; I Generalov; Georgy A Nevinsky; Dirk Roggenbuck Journal: Immunol Res Date: 2013-07 Impact factor: 2.829
Authors: Matthew L Stoll; L Wayne Duck; Margaret H Chang; Robert A Colbert; Peter A Nigrovic; Susan D Thompson; Charles O Elson Journal: Clin Immunol Date: 2020-05-11 Impact factor: 3.969
Authors: Filip De Keyser; Dominique Baeten; Filip Van den Bosch; Elli Kruithof; Gust Verbruggen; Herman Mielants; Eric Veys Journal: Drugs Date: 2004 Impact factor: 9.546
Authors: Mark J Asquith; Patrick Stauffer; Sean Davin; Claire Mitchell; Phoebe Lin; James T Rosenbaum Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995